Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.
 |
Vidyya |
|
Ars Medica Home |
|
Vidyya Archives |
|
Search Vidyya |
|
Ex Libris |
|
Subscriptions |
|
About Vidyya |
|
|
|
In Today's Vidyya Information from the American College of Cardiology's annual meeting is highlighted in today's issue. |
|
Scientific Experts And Airline Industry Call For Further Study Of Venous Thrombosis A consultation of international experts, convened by the World Health Organization (WHO) on 12-13 March 2001, reviewed the existing state of evidence on air travel and venous thrombosis and concluded that further research is needed into the matter. More... |
|
Additional Information About Long-Term Benefits Of Pravastatin Therapy Gleaned From Follow Up Of A Landmark Lipid Trial The results of a follow-up analysis of the landmark Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study provide important new evidence regarding the benefits of cholesterol-lowering treatment with pravastatin for women with a prior history of coronary heart disease. More... |
|
Study Demonstrates Differences In Blood Pressure And Edema Between Celebrex® And Vioxx®
Study results presented yesterday at the American College of Cardiology's (ACC) annual meeting showed that elderly hypertensive osteoarthritis (OA) patients taking Vioxx® (rofecoxib) experienced a statistically significant increase (approximately 3 mm Hg) in mean systolic blood pressure compared with those taking Celebrex® (celecoxib capsules). In comparison, Celebrex patients showed no increase in mean systolic blood pressure. More... |
|
Prior To Coronary Interventions, Injection With Lovenox ® May Be Of Potential Benefit An analysis of more than 6,000 patients treated for acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction), indicates that those who received the blood thinner Lovenox (enoxaparin sodium) Injection prior to undergoing percutaneous coronary intervention (PCI) fared better than patients given unfractionated heparin. The analysis, based on the landmark ESSENCE and TIMI 11B* trials, was presented yesterday at the 50th Annual Scientific Session of the American College of Cardiology. More... |
|
Viagra Safe For Men With Healthy Hearts Pfizer Inc. said today that men with erectile dysfunction (ED) who have been prescribed Viagra (sildenafil citrate) do not have an increased risk of heart attack or death from ischemic heart disease, according to results from the first phase of a large-scale, observational study of Viagra presented at the annual meeting of the American College of Cardiology (ACC). More... |
Ars Medica Home | Ex Libris | Vidyya |
Subscription Information | About Vidyya | Vidyya Archives |
Editor: Susan K. Boyer, RN
© RAmEx Ars Medica, Inc. All rights reserved.